<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Climacteric</journal-id><journal-id journal-id-type="iso-abbrev">Climacteric</journal-id><journal-id journal-id-type="publisher-id">CMT</journal-id><journal-title-group><journal-title>Climacteric</journal-title></journal-title-group><issn pub-type="ppub">1369-7137</issn><issn pub-type="epub">1473-0804</issn><publisher><publisher-name>Informa Healthcare</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22853318</article-id><article-id pub-id-type="pmc">3793274</article-id><article-id pub-id-type="doi">10.3109/13697137.2012.688079</article-id><article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>The evolution of selective estrogen receptor modulators in osteoporosis therapy</article-title></title-group><contrib-group><contrib id="a1" contrib-type="author" corresp="yes"><name><surname>Hadji</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><aff id="AF0001"><institution>Department of Endocrinology, Reproductive Medicine, and Osteoporosis, Philipps-University of Marburg</institution>, <addr-line>Marburg</addr-line>, <country>Germany</country></aff></contrib-group><author-notes><corresp id="c1">Correspondence: Professor P. Hadji, <institution>Department of Endocrinology, Reproductive Medicine, and Osteoporosis, Philipps-University of Marburg</institution>, <addr-line>Baldingerstrasse, 35033 Marburg</addr-line>, <country>Germany</country></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>1</day><month>8</month><year>2012</year></pub-date><volume>15</volume><issue>6</issue><fpage>513</fpage><lpage>523</lpage><history><date date-type="received"><day>22</day><month>12</month><year>2011</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2012 International Menopause Society</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>International Menopause Society</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by-nc/3.0/" license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="13697137.2012.688079.pdf"/><abstract><p>Selective estrogen receptor modulators (SERMs), which exhibit estrogen receptor agonist or antagonist activity based on the target tissue, have evolved through multiple generations for the prevention and/or treatment of postmenopausal osteoporosis. An ideal SERM would protect bone without stimulating the breast or endometrium. Raloxifene, lasofoxifene, and bazedoxifene have demonstrated unique preclinical profiles. Raloxifene, lasofoxifene, and bazedoxifene have shown significant reduction in the risk of vertebral fracture and improvement in bone mineral density versus placebo in postmenopausal women with osteoporosis. Raloxifene has been shown to reduce the risk of non-vertebral fractures in women with severe prevalent fractures at baseline. Lasofoxifene 0.5 mg, but not lasofoxifene 0.25 mg, has shown reduction in the incidence of non-vertebral fractures. Bazedoxifene 20 mg has been associated with a significant reduction in the risk of non-vertebral fracture versus placebo and raloxifene 60 mg in women at higher baseline fracture risk. Neither raloxifene, lasofoxifene, nor bazedoxifene has shown an increase in the incidence of endometrial hyperplasia or carcinoma. All SERMs have been associated with increased venous thromboembolic events and hot flushes. SERMs are effective alternatives for women who cannot tolerate or are unwilling to take bisphosphonates and may be appropriate for women at higher risk of fracture, particularly younger women who expect to remain on therapy for many years and are concerned about the long-term safety of bisphosphonates.</p></abstract><kwd-group><kwd>POSTMENOPAUSAL</kwd><kwd>OSTEOPOROSIS</kwd><kwd>SERMs</kwd><kwd>BAZEDOXIFENE</kwd><kwd>RALOXIFENE</kwd><kwd>LASOFOXIFENE</kwd></kwd-group></article-meta></front><body><sec id="ss1"><title>INTRODUCTION</title><p>Selective estrogen receptor modulators (SERMs) have been found to be effective pharmacological interventions for the management of a variety of diseases related to estrogen deficiency in postmenopausal women<sup><xref ref-type="bibr" rid="CIT0001">1</xref></sup>. SERMs bind to estrogen receptors (ER) &#x003b1; and &#x003b2; and have agonist or antagonist activity depending on the compound itself as well as the target tissue<sup><xref ref-type="bibr" rid="CIT0002">2</xref>,<xref ref-type="bibr" rid="CIT0003">3</xref></sup>. ER&#x003b1; and ER&#x003b2; are disproportionally distributed in the brain<sup><xref ref-type="bibr" rid="CIT0004">4</xref></sup>, uterus<sup><xref ref-type="bibr" rid="CIT0005">5</xref></sup>, bone<sup><xref ref-type="bibr" rid="CIT0006">6</xref>,<xref ref-type="bibr" rid="CIT0007">7</xref></sup>, breast<sup><xref ref-type="bibr" rid="CIT0005">5</xref></sup>, ovary<sup><xref ref-type="bibr" rid="CIT0005">5</xref></sup>, and liver<sup><xref ref-type="bibr" rid="CIT0008">8</xref></sup> (<xref ref-type="fig" rid="F1">Figure 1</xref>). Based on this varied distribution of ERs, an optimally designed SERM would exhibit beneficial effects on the skeleton, cardiovascular system (e.g. lipid profile), and central nervous system (e.g. vasomotor effects), without having adverse effects on the endometrium or breast<sup><xref ref-type="bibr" rid="CIT0002">2</xref></sup>.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Relative agonist and antagonist activities of selective estrogen receptor modulators (SERMs) in different target tissues: (a) bone, (b) endometrium, (c) breast. BZA, bazedoxifene; LAS, lasofoxifene; RLX, raloxifene</p></caption><graphic xlink:href="CMT-15-513-g001"/></fig><p>Tamoxifen, a first-generation SERM, exhibits ER antagonist activity in the breast and is considered the first-line treatment for ER-positive breast cancer in premenopausal women<sup><xref ref-type="bibr" rid="CIT0009">9</xref></sup>. It has also been shown to be effective in preventing breast cancer in women regardless of age<sup><xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0011">11</xref></sup>. However, an analysis of data from the Breast Cancer Prevention Trial indicated that the risks of endometrial cancer, stroke, pulmonary embolism, and deep vein thrombosis associated with tamoxifen were elevated in women aged 50 years and older<sup><xref ref-type="bibr" rid="CIT0011">11</xref></sup>, suggesting that the side-effect profile of tamoxifen may not be appropriate for breast cancer prevention, especially in older postmenopausal women<sup><xref ref-type="bibr" rid="CIT0012">12</xref></sup>.</p><p>Tamoxifen has demonstrated ER agonist activity in the skeleton, with favorable effects on bone mineral density (BMD) in postmenopausal women (a decrease in BMD has been seen in premenopausal women)<sup><xref ref-type="bibr" rid="CIT0013">13</xref></sup>. Tamoxifen has been shown to significantly reduce the overall risk of fracture in postmenopausal women with osteoporosis and reduce the risk of hip fracture in women aged &#x02265;&#x02009;50 years with a first osteoporotic fracture<sup><xref ref-type="bibr" rid="CIT0014">14</xref></sup>. It has also been shown to decrease low density lipoprotein (LDL) cholesterol<sup><xref ref-type="bibr" rid="CIT0010">10</xref></sup> and the risk of cardiovascular disease<sup><xref ref-type="bibr" rid="CIT0009">9</xref></sup>. Tamoxifen exhibits ER agonist activity in the uterus and is associated with an increased risk of endometrial cancer<sup><xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0015">15</xref></sup>.</p><p>Raloxifene (RLX) is the best characterized example of a second-generation SERM<sup><xref ref-type="bibr" rid="CIT0010">10</xref></sup>. It is approved for prevention and treatment of postmenopausal osteoporosis in the Unites States and European Union and for the prevention of breast cancer in the United States<sup><xref ref-type="bibr" rid="CIT0016">16</xref>,<xref ref-type="bibr" rid="CIT0017">17</xref></sup>. In a recent combined analysis of multiple clinical trials that evaluated RLX and tamoxifen for the prevention of invasive breast cancer, benefit/risk indices were constructed for risk groups based on factors such as age, ethnicity, breast cancer risk, and the presence of a uterus. For RLX versus tamoxifen, there were more groups with stronger evidence that the benefits of treatment outweigh its risks in postmenopausal women over 50 years of age with a uterus<sup><xref ref-type="bibr" rid="CIT0012">12</xref></sup>. Additionally, long-term use of RLX was associated with a significant decrease in all-cause mortality compared with placebo (<italic>p</italic> =&#x02009;0.05) in a pooled analysis of data from studies among older postmenopausal women<sup><xref ref-type="bibr" rid="CIT0018">18</xref></sup>.</p><p>The third-generation SERMs, lasofoxifene (LAS) and bazedoxifene (BZA), are approved in the European Union for the treatment of postmenopausal osteoporosis in women at increased risk of fracture<sup><xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0019">19</xref>,<xref ref-type="bibr" rid="CIT0020">20</xref></sup>. This article summarizes how SERMs have evolved in osteoporosis treatment and discusses the molecular details of how SERMs exert their bone-sparing effects. The key clinical trial results with SERMs developed for the management of osteoporosis will also be reviewed.</p></sec><sec id="ss2"><title>SERMs: MECHANISM OF ACTION</title><p>Upon ligand binding, ERs adopt different conformations and spontaneously dimerize. Once dimerized, the ER complex becomes capable of modulating gene transcription<sup><xref ref-type="bibr" rid="CIT0021">21</xref></sup>. This modulation can occur through agonist or antagonist binding to the ER complex. Agonist binding recruits coactivators to the ER complex, which triggers gene transcription, while antagonist binding recruits corepressors to the ER complex, which prevents transcription<sup><xref ref-type="bibr" rid="CIT0021">21</xref></sup>.</p><p>It has been shown that SERMs elicit different gene expression profiles from one another and, in some tissues, from estrogens<sup><xref ref-type="bibr" rid="CIT0022">22</xref></sup>. The SERM&#x02013;ER complex structure differs from that attained with traditional agonists or antagonists, based on characteristics of the SERM<sup><xref ref-type="bibr" rid="CIT0023">23</xref></sup>. Individual SERM&#x02013;ER complexes have distinct activities in different tissues<sup><xref ref-type="bibr" rid="CIT0021">21</xref></sup>. Similar to estrogens, SERMs generally function as agonists in bone<sup><xref ref-type="bibr" rid="CIT0021">21</xref></sup> through the activity of osteoclasts and osteoblasts, and may be considered to have a more physiologic mechanism of action compared with other pharmacologic agents (e.g. bisphosphonates). SERMs have been shown to directly decrease osteoclast differentiation and bone resorption activity, while stimulating osteoblast activity and proliferation in bone marrow cultures from neonatal mice<sup><xref ref-type="bibr" rid="CIT0024">24</xref></sup>. SERMs may also increase the activity of osteoblasts by stimulating osteoprotegerin expression and decreasing nuclear factor-&#x003ba;B ligand (RANKL) levels. Lower ratios of RANKL to osteoprotegerin have been associated with increased osteoblastic activity and preservation of BMD<sup><xref ref-type="bibr" rid="CIT0025">25</xref></sup>.</p></sec><sec id="ss3"><title>PRECLINICAL EVALUATION OF SERMs</title><sec id="ss4"><title>Raloxifene</title><p>In an ovariectomized (OVX) rat model, treatment with RLX 3.0 mg/kg/day for 6 months was associated with significant increases in lumbar vertebral and proximal tibia BMD (<italic>p</italic> &#x0003c;&#x02009;0.001 for both) and significant increases in lumbar vertebral (<italic>p</italic> &#x0003c;&#x02009;0.05) and femoral neck (<italic>p</italic> &#x0003c;&#x02009;0.01) bone strength compared with OVX controls<sup><xref ref-type="bibr" rid="CIT0026">26</xref></sup>. Treatment of OVX rats with RLX 0.1&#x02013;1.0 mg/kg/day for 6 months showed a significant increase in uterine wet weight (<italic>p</italic> &#x0003c;&#x02009;0.05), but uterine histology did not differ from control<sup><xref ref-type="bibr" rid="CIT0027">27</xref></sup>. RLX has been shown to prevent the development of mammary tumors during 4.5 months of treatment in rats, with a reduction in incidence of 55% and 57% (<italic>p</italic> &#x0003c;&#x02009;0.001 for both) compared with placebo for RLX 60 and 20 mg/day, respectively<sup><xref ref-type="bibr" rid="CIT0028">28</xref></sup>.</p></sec><sec id="ss5"><title>Lasofoxifene</title><p>LAS 60, 150, and 300 &#x003bc;g/kg/day prevented ovariectomy-induced reductions in BMD through 1 year of treatment in OVX rats and significantly increased the ultimate strength of the L4 lumbar vertebra by 37%, 40%, and 47%, respectively, compared with control (<italic>p</italic> &#x0003c;&#x02009;0.05)<sup><xref ref-type="bibr" rid="CIT0029">29</xref></sup>. These doses of LAS were associated with a significant increase in uterine wet weight (16%, 20%, and 11% for LAS 60, 150, and 300 &#x003bc;g/kg/day, respectively) compared with control (<italic>p</italic> &#x0003c;&#x02009;0.05); there were no significant changes in uterine histology<sup><xref ref-type="bibr" rid="CIT0029">29</xref></sup>. In a rat model of <italic>N</italic>-nitroso-<italic>N</italic>-methylurea-induced mammary tumors, treatment with LAS 0.1&#x02013;10 mg/kg/day for 8 weeks delayed the formation of mammary tumors by 17&#x02013;32 days compared with vehicle control<sup><xref ref-type="bibr" rid="CIT0030">30</xref></sup>.</p></sec><sec id="ss6"><title>Bazedoxifene</title><p>In OVX rats, treatment with BZA 0.1, 0.3, 1.0, and 3.0 mg/kg/day for 6 weeks showed significant, dose-dependent increases in BMD (<italic>p</italic> &#x0003c;&#x02009;0.01 vs. OVX control) and increased compressive strength of the L4 vertebra (<italic>p</italic> &#x02264;&#x02009;0.05) compared with vehicle control<sup><xref ref-type="bibr" rid="CIT0003">3</xref>,<xref ref-type="bibr" rid="CIT0031">31</xref></sup>. After treatment with BZA 3.0 mg/kg/day for 6 weeks, uterine wet weights of OVX rats were not different compared with vehicle control<sup><xref ref-type="bibr" rid="CIT0031">31</xref></sup>. Similarly, OVX rats treated with BZA 0.3 mg/kg/day for 1 year showed uterine wet weights that were not different from those of OVX control rats<sup><xref ref-type="bibr" rid="CIT0032">32</xref></sup>. BZA did not induce proliferation of the MCF-7 breast cancer cell line during 7 days of treatment<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup>. In OVX mice treated for 7 days with BZA 3.0 mg/kg/day, BZA did not stimulate breast tissue, as measured by mammary gland end bud formation<sup><xref ref-type="bibr" rid="CIT0033">33</xref></sup>. In an OVX sexually immature mouse model, treatment with BZA 2.0 mg/kg/day for 14 days resulted in ductal branch point invasion that was not different from that with vehicle control (<italic>p</italic> &#x0003e;&#x02009;0.05)<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>.</p></sec><sec id="ss7"><title>Preclinical comparison of SERMs</title><p>Several studies have been conducted to compare the preclinical profile of second- and third-generation SERMs such as RLX, LAS, and BZA. In OVX rats, the effects of BZA 0.3 mg/kg/day for 6 weeks on BMD, histomorphometry, and total cholesterol were comparable to those with RLX 3.0 mg/kg/day<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup>. Uterine and mammary gland responses to treatment with different SERMs were evaluated after 7 days in a study of OVX mice<sup><xref ref-type="bibr" rid="CIT0033">33</xref></sup>. Treatment with RLX, LAS, and BZA at a dose of 3.0 mg/kg/day showed small increases in uterine wet weight versus vehicle control (<italic>p</italic> &#x0003c;&#x02009;0.05), with the smallest increase for BZA (44%) compared with RLX (79%) or LAS (217%)<sup><xref ref-type="bibr" rid="CIT0033">33</xref></sup>. Consistent with what was seen with BZA, RLX and LAS did not stimulate breast tissue, as measured by mammary gland end bud formation<sup><xref ref-type="bibr" rid="CIT0033">33</xref></sup>. BZA and RLX, but not LAS, were shown to reverse estradiol-induced terminal end bud formation<sup><xref ref-type="bibr" rid="CIT0033">33</xref></sup>.</p><p>In an OVX sexually immature mouse model, the minimum doses of RLX, LAS, and BZA that were required to maximally inhibit conjugated estrogen (CE)-induced increases in uterine wet weight were determined (10 mg/kg/day for RLX, 2 mg/kg/day for LAS, and 2 mg/kg/day for BZA), and the effects of these SERMs on uterine and mammary tissue were evaluated over 14 days of treatment<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>. Uterine wet weights increased compared with vehicle control in the order LAS 2 mg/kg/day &#x0003e; RLX 10 mg/kg/day &#x0003e; BZA 2 mg/kg/day, with significant differences (<italic>p</italic> &#x0003c;&#x02009;0.05) between groups<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>. BZA 2 mg/kg/day and RLX 10 mg/kg/day were more effective at antagonizing CE-induced uterine stimulation than LAS 2 mg/kg/day<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>. In the mammary gland, treatment with BZA 2 mg/kg/day was associated with lower amphiregulin mRNA expression, a measure of mammary gland ER agonist activity, compared with RLX 10 mg/kg/day or LAS 2 mg/kg/day (<italic>p</italic> &#x0003c;&#x02009;0.05 for the difference between each group)<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>. In the mammary gland whole mount assay, BZA 2 mg/kg/day and RLX 10 mg/kg/day, but not LAS 2 mg/kg/day, had a similar number of ductal branch points as vehicle control<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>. BZA 2 mg/kg/day was more effective than RLX 10 mg/kg/day or LAS 2 mg/kg/day at preventing ductal tree fat pad invasion (<italic>p</italic> &#x0003c;&#x02009;0.05 for both comparisons)<sup><xref ref-type="bibr" rid="CIT0034">34</xref></sup>.</p><p>The effects of different SERMs (BZA, 4-hydroxytamoxifen, endoxifen, RLX) and the pure antiestrogen fulvestrant on the proliferation of hormone-dependent and -independent breast cancer cells were evaluated<sup><xref ref-type="bibr" rid="CIT0035">35</xref></sup>. Using protein expression assays and molecular modeling studies of the binding of each SERM to ER&#x003b1;, BZA was shown to inhibit hormone-dependent cell growth and to regulate ER&#x003b1; and cyclin D1 in hormone-independent cells in a manner distinct from all of the other SERMs<sup><xref ref-type="bibr" rid="CIT0035">35</xref></sup>. Gene expression profiling has shown different patterns of gene expression for BZA, RLX, and LAS, with more similarity between RLX and BZA than between either of these agents and LAS<sup><xref ref-type="bibr" rid="CIT0036">36</xref></sup>. The results of these studies indicate that SERMs have distinct preclinical profiles. The doses required to achieve similar bone-protective effects vary as much as 10-fold among SERMs<sup><xref ref-type="bibr" rid="CIT0002">2</xref>,<xref ref-type="bibr" rid="CIT0003">3</xref></sup>, and the ER agonist and antagonist profiles in uterine and breast tissue also differ among SERMs<sup><xref ref-type="bibr" rid="CIT0033">33</xref>,<xref ref-type="bibr" rid="CIT0034">34</xref></sup>.</p></sec></sec><sec id="ss8"><title>CLINICAL TRIALS OF SERMs</title><p>RLX, LAS, and BZA have each been evaluated in phase-3 clinical trials conducted in postmenopausal women with osteoporosis.</p><sec id="ss9"><title>Raloxifene</title><p>The phase-3, Multiple Outcomes of Raloxifene Evaluation (MORE) trial evaluated RLX 60 and 120 mg/day for 3 years in 7705 postmenopausal women with osteoporosis<sup><xref ref-type="bibr" rid="CIT0037">37</xref>,<xref ref-type="bibr" rid="CIT0038">38</xref></sup>. The Continuing Outcomes Relevant to Evista (CORE) trial was a 4-year extension study that enrolled 4011 women who were previously enrolled in the MORE trial<sup><xref ref-type="bibr" rid="CIT0039">39</xref>,<xref ref-type="bibr" rid="CIT0040">40</xref></sup>. In the CORE trial, women who had received RLX 60 and 120 mg during the MORE trial were all given RLX 60 mg, and women who had received placebo continued to do so.</p><p>At 3 years, RLX 60 and 120 mg reduced the incidence of new vertebral fractures by 30% (relative risk (RR) 0.7; 95% confidence interval (CI) 0.5&#x02013;0.8) and 50% (RR 0.5; 95% CI 0.4&#x02013;0.7), respectively, versus placebo in the MORE trial (<xref ref-type="table" rid="T1">Table 1</xref>)<sup><xref ref-type="bibr" rid="CIT0037">37</xref></sup>. The risk of non-vertebral fracture was similar among the RLX and placebo groups at 3 years in the MORE trial<sup><xref ref-type="bibr" rid="CIT0037">37</xref></sup> and at 8 years in the CORE trial<sup><xref ref-type="bibr" rid="CIT0041">41</xref></sup>. In a reanalysis of data from women enrolled in the MORE study who did not have baseline vertebral fractures (<italic>n</italic> =&#x02009;3204)<sup><xref ref-type="bibr" rid="CIT0042">42</xref></sup>, RLX 60 mg was shown to reduce the risk of vertebral fractures and all clinical fractures in women with osteoporosis or osteopenia as defined by baseline hip BMD based on the Third National Health and Nutrition Examination Survey (NHANES III) database. In a <italic>post hoc</italic> secondary analysis of data from women enrolled in the MORE trial with the most severe prevalent vertebral fractures at baseline (semiquantitative assessment =&#x02009;3; <italic>n</italic> =&#x02009;614), RLX 60 mg was associated with a significantly decreased risk of non-vertebral fracture at 3 years (<italic>p</italic> =&#x02009;0.046)<sup><xref ref-type="bibr" rid="CIT0043">43</xref></sup>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Bone effects of SERMs in phase-3 treatment studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">
<italic>Raloxifene</italic>
<break/>(MORE; <italic>n</italic> =&#x02009;7705)<sup><xref ref-type="bibr" rid="CIT0037">37</xref></sup>, (CORE; <italic>n</italic> =&#x02009;4011)<sup><xref ref-type="bibr" rid="CIT0041">41</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Lasofoxifene</italic>
<break/>(PEARL; <italic>n</italic> =&#x02009;8556)<sup><xref ref-type="bibr" rid="CIT0047">47</xref>,<xref ref-type="bibr" rid="CIT0076">76</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Bazedoxifene</italic>
<break/>(<italic>n</italic> =&#x02009;7492 and <italic>n</italic> =&#x02009;4216)<sup><xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0056">56</xref></sup>
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>60 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>120 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.25 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.5 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>20 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>40 mg</italic>
</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">
<italic>Vertebral fracture risk reduction</italic> (%)<xref ref-type="fn" rid="T1-F1">*</xref></td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">30% (RR 0.7; 95% CI 0.5&#x02013;0.8)</td><td rowspan="1" colspan="1">50% (RR 0.5; 95% CI 0.4&#x02013;0.7)</td><td rowspan="1" colspan="1">31%<xref ref-type="fn" rid="T1-F2"><sup>&#x02020;</sup></xref> (HR 0.69; 95% CI 0.55&#x02013;0.87)</td><td rowspan="1" colspan="1">42%<xref ref-type="fn" rid="T1-F2"><sup>&#x02021;</sup></xref> (HR 0.58; 95% CI 0.45&#x02013;0.73)</td><td rowspan="1" colspan="1">42%<xref ref-type="fn" rid="T1-F4">**</xref> (HR 0.58; 95% CI 0.38&#x02013;0.89)</td><td rowspan="1" colspan="1">37%<xref ref-type="fn" rid="T1-F4">**</xref> (HR 0.63; 95% CI 0.42&#x02013;0.96)</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">31%<xref ref-type="fn" rid="T1-F2"><sup>&#x02021;</sup></xref> (HR 0.69; 95% CI 0.57&#x02013;0.83)</td><td rowspan="1" colspan="1">42%<xref ref-type="fn" rid="T1-F2"><sup>&#x02021;</sup></xref> (HR 0.58; 95% CI 0.47&#x02013;0.70)</td><td rowspan="1" colspan="1">35% (HR 0.65; 95% CI 0.46&#x02013;0.91)</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Non-vertebral fracture risk reduction</italic> (%)<xref ref-type="fn" rid="T1-F1">*</xref></td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">10% (RR 0.9; 95% CI 0.8&#x02013;1.1 for pooled RLX 60/120 mg)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td colspan="2" rowspan="1">40%<xref ref-type="fn" rid="T1-F4">**</xref> (HR 0.60; 95% CI 0.37&#x02013;0.95 for pooled BZA 20/40 mg in a <italic>post hoc</italic> analysis of subjects at higher risk of fracture)</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">10% (HR 0.90; 95% CI 0.76&#x02013;1.06)</td><td rowspan="1" colspan="1">24%<xref ref-type="fn" rid="T1-F2"><sup>&#x02020;</sup></xref> (HR 0.76; 95% CI 0.64&#x02013;0.91)</td><td colspan="2" rowspan="1">31% (HR 0.69; 95% CI 0.42&#x02013;1.13 for pooled BZA 20/40 mg in a <italic>post hoc</italic> analysis of subjects at higher risk of fracture)</td></tr><tr><td rowspan="1" colspan="1">8 years</td><td colspan="2" rowspan="1">0% (RR 1.0; 95% CI 0.8&#x02013;1.2 for pooled RLX 60/120 mg)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td colspan="2" rowspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Mean change from baseline in lumbar spine BMD</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">2.6%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">2.7%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">2.2%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">2.4%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">3.0%<xref ref-type="fn" rid="T1-F5"><sup>&#x02020;&#x02020;</sup></xref> (95% CI 2.6&#x02013;3.3%) vs. placebo</td><td rowspan="1" colspan="1">3.1%<xref ref-type="fn" rid="T1-F5"><sup>&#x02020;&#x02020;</sup></xref> (95% CI 2.8&#x02013;3.5%) vs. placebo</td><td colspan="2" rowspan="1">2.1%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref> for pooled BZA 20/40 mg</td></tr><tr><td rowspan="1" colspan="1">7 years</td><td colspan="2" rowspan="1">4.3%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref> for pooled RLX 60/120 mg</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Median change from baseline in urinary C-telopeptide</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;48% (95% CI &#x02212;&#x02009;51 to &#x02212;&#x02009;45%)</td><td rowspan="1" colspan="1">&#x02013;53% (95% CI &#x02212;&#x02009;55 to &#x02212;&#x02009;48%)</td><td rowspan="1" colspan="1">&#x02212;&#x02009;46%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02212;&#x02009;49%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02212;&#x02009;34.0%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02212;&#x02009;31.5%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Median change from baseline in serum osteocalcin</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">1 year</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;45% (95% CI &#x02212;&#x02009;47 to &#x02212;&#x02009;44%)</td><td rowspan="1" colspan="1">&#x02013;46% (95% CI &#x02212;&#x02009;50 to &#x02212;&#x02009;43%)</td><td rowspan="1" colspan="1">&#x02212;&#x02009;37%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02212;&#x02009;39%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02212;&#x02009;26.3%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">31.1%<xref ref-type="fn" rid="T1-F3"><sup>&#x02021;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>SERM, selective estrogen receptor modulator; MORE, Multiple Outcomes of Raloxifene Evaluation; CORE, Continuing Outcomes Relevant to Evista; PEARL, Postmenopausal Evaluation And Risk-reduction with Lasofoxifene; RR, relative risk; CI, confidence interval; HR, hazard ratio; RLX, raloxifene; BZA, bazedoxifene; BMD, bone mineral density</p></fn><fn id="T1-F1"><p>*, HR and RR versus placebo;</p></fn><fn id="T1-F2"><p><sup>&#x02020;</sup>, <italic>p</italic> &#x0003c;&#x02009;0.01 vs. placebo;</p></fn><fn id="T1-F3"><p><sup>&#x02021;</sup>, <italic>p</italic> &#x0003c;&#x02009;0.001 vs. placebo;</p></fn><fn id="T1-F4"><p>**, <italic>p</italic> &#x0003c;&#x02009;0.05 vs. placebo;</p></fn><fn id="T1-F5"><p><sup>&#x02020;&#x02020;</sup>, % reduction vs. placebo (not vs. baseline)</p></fn></table-wrap-foot></table-wrap><p>Relative to placebo, lumbar spine BMD values were increased by 2.6% for RLX 60 mg and by 2.7% for RLX 120 mg (<italic>p</italic> &#x0003c;&#x02009;0.001) at 3 years<sup><xref ref-type="bibr" rid="CIT0037">37</xref></sup>. BMD changes were evaluated at 7 years in a substudy of the CORE study. Lumbar spine BMD values were increased by 2.2% in the pooled RLX 60/120 mg group compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.01)<sup><xref ref-type="bibr" rid="CIT0041">41</xref></sup>.</p><p>Hot flushes were more common in women taking RLX compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.001) over 8 years of treatment in the MORE and CORE trials<sup><xref ref-type="bibr" rid="CIT0040">40</xref></sup>.</p><p>The Raloxifene Use for The Heart (RUTH) trial investigated the effects of RLX 60 mg in a population of postmenopausal women with cardiac heart disease or risk factors for cardiac heart disease (<italic>n</italic> =&#x02009;10 101)<sup><xref ref-type="bibr" rid="CIT0044">44</xref></sup>. After a median follow-up of 5.6 years, there was no significant difference between RLX 60 mg and placebo in the risk of primary coronary events, including death from coronary causes, myocardial infarction, or hospitalization for an acute coronary syndrome other than myocardial infarction (hazard ratio (HR) 0.95; 95% CI 0.84&#x02013;1.07). The risk of invasive breast cancer in this trial was lower for RLX 60 mg than for placebo (HR 0.56; 95% CI 0.38&#x02013;0.83; absolute risk reduction, 1.2 invasive breast cancers per 1000 women)<sup><xref ref-type="bibr" rid="CIT0044">44</xref></sup>. There was no significant difference among groups in the overall risk of stroke in the RUTH trial, although RLX 60 mg was associated with an increased risk of fatal stroke compared with placebo (HR 1.49; 95% CI 1.00&#x02013;2.24; <xref ref-type="table" rid="T2">Table 2</xref>)<sup><xref ref-type="bibr" rid="CIT0044">44</xref></sup>.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Cardiovascular safety profiles of SERMs in phase-3 treatment studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">
<italic>Raloxifene</italic>
<break/>(MORE; <italic>n</italic> =&#x02009;7705)<sup><xref ref-type="bibr" rid="CIT0038">38</xref></sup>, (RUTH; <italic>n</italic> =&#x02009;10 101)<sup><xref ref-type="bibr" rid="CIT0044">44</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Lasofoxifene</italic>
<break/>(PEARL; <italic>n</italic> =&#x02009;8556)<sup><xref ref-type="bibr" rid="CIT0048">48</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Bazedoxifene</italic>
<break/>(<italic>n</italic> =&#x02009;7492 and <italic>n</italic> =&#x02009;4216)<sup><xref ref-type="bibr" rid="CIT0054">54</xref>,<xref ref-type="bibr" rid="CIT0058">58</xref></sup>
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>60 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>120 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.25 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.5 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>20 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>40 mg</italic>
</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">
<italic>Incidence of venous thromboembolism<xref ref-type="fn" rid="T2-F1">*</xref></italic>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">RR 3.1 (95% CI 1.5&#x02013;6.2) for pooled RLX 60/120 mg</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">HR<xref ref-type="fn" rid="T2-F2"><sup>&#x02020;</sup></xref> 1.6 (95% CI 0.68&#x02013;3.94)</td><td rowspan="1" colspan="1">HR<xref ref-type="fn" rid="T2-F2"><sup>&#x02020;</sup></xref> 1.7 (95% CI 0.79&#x02013;4.07)</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">HR 2.67<xref ref-type="fn" rid="T2-F3"><sup>&#x02021;</sup></xref> (95% CI 1.55&#x02013;4.58)</td><td rowspan="1" colspan="1">HR 2.06<xref ref-type="fn" rid="T2-F4">**</xref> (95% CI 1.17&#x02013;3.61)</td><td rowspan="1" colspan="1">HR<xref ref-type="fn" rid="T2-F2"><sup>&#x02020;</sup></xref> 1.5 (95% CI 0.68&#x02013;3.35)</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Incidence of total stroke</italic>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">HR<xref ref-type="fn" rid="T2-F2"><sup>&#x02020;</sup></xref> 0.9 (95% CI 0.40&#x02013;1.86)</td><td rowspan="1" colspan="1">HR<xref ref-type="fn" rid="T2-F2"><sup>&#x02020;</sup></xref> 1.0 (95% CI 0.49&#x02013;2.17)</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">HR 1.10 (95% CI 0.92&#x02013;1.32)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">HR 0.61 (95% CI 0.39&#x02013;0.96)</td><td rowspan="1" colspan="1">HR 0.64 (95% CI 0.41&#x02013;0.99)</td><td rowspan="1" colspan="1">HR<xref ref-type="fn" rid="T2-F2"><sup>&#x02020;</sup></xref> 0.8 (95% CI 0.43&#x02013;1.63)</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>SERM, selective estrogen receptor modulator; MORE, Multiple Outcomes of Raloxifene Evaluation; RUTH, Raloxifene Use for The Heart (phase-3 cardiovascular effects study); PEARL, Postmenopausal Evaluation And Risk-reduction with Lasofoxifene; RR, relative risk; RLX, raloxifene; HR, hazard ratio; CI, confidence interval</p></fn><fn id="T2-F1"><p>
<italic>*,</italic> HR and RR versus placebo;</p></fn><fn id="T2-F2"><p><sup>&#x02020;</sup>, adjudicated data;</p></fn><fn id="T2-F3"><p><sup>&#x02021;</sup>, <italic>p</italic> =&#x02009;0.001 vs. placebo;</p></fn><fn id="T2-F4"><p>**, <italic>p</italic> =&#x02009;0.01 vs. placebo</p></fn></table-wrap-foot></table-wrap><p>For subjects in the MORE trial, the risk of venous thromboembolism (VTE) was higher with both doses of RLX (60 and 120 mg combined) than with placebo (RR 3.1; 95% CI 1.5&#x02013;6.2; <xref ref-type="table" rid="T2">Table 2</xref>)<sup><xref ref-type="bibr" rid="CIT0037">37</xref></sup>. In an 8-year safety evaluation of the MORE and CORE studies, the risk of VTE was determined to be 1.7 times higher with RLX 60/120 mg combined than with placebo. There was no significant difference in the total incidence of stroke between RLX 60/120 mg and placebo<sup><xref ref-type="bibr" rid="CIT0040">40</xref></sup>.</p><p>Lipid effects from the MORE trial were not reported, but in a 2-year, multicenter, double-blind, placebo-controlled study of postmenopausal women with normal or low BMD (<italic>n</italic> =&#x02009;601), RLX 60 mg was associated with a significant decrease from baseline in total and LDL cholesterol (<italic>p</italic> &#x0003c;&#x02009;0.05 vs. placebo) and with no significant changes from baseline in high density lipoprotein (HDL) cholesterol or triglycerides (<xref ref-type="table" rid="T3">Table 3</xref>)<sup><xref ref-type="bibr" rid="CIT0045">45</xref></sup>.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Lipid effects. Data are given as median (standard error) percent change from baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">
<italic>Raloxifene</italic>
<break/>
<italic>Phase-3 prevention study</italic>
<break/>(<italic>n</italic> =&#x02009;601)<sup><xref ref-type="bibr" rid="CIT0045">45</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Lasofoxifene</italic>
<break/>
<italic>Phase-3 treatment study</italic>
<break/>(PEARL; <italic>n</italic> =&#x02009;8556)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Bazedoxifene</italic>
<break/>
<italic>Phase-3 treatment study</italic>
<break/>(<italic>n</italic> =&#x02009;7492)<sup><xref ref-type="bibr" rid="CIT0054">54</xref></sup>
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>60 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>120 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.25 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.5 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>20 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>40 mg</italic>
</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">
<italic>Total cholesterol</italic>
</td></tr><tr><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">&#x02212;&#x02009;6.4 (1.1)<xref ref-type="fn" rid="T3-F1">*</xref></td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02212;&#x02009;3.8<xref ref-type="fn" rid="T3-F2"><sup>&#x02020;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02212;&#x02009;3.5<xref ref-type="fn" rid="T3-F2"><sup>&#x02020;</sup></xref>
</td></tr><tr><td colspan="7" rowspan="1">
<italic>LDL cholesterol</italic>
</td></tr><tr><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">&#x02212;&#x02009;10.1 (1.4)<xref ref-type="fn" rid="T3-F1">*</xref></td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02212;&#x02009;16.2% (95% CI &#x02212;&#x02009;19.7 to &#x02212;&#x02009;12.7%)</td><td rowspan="1" colspan="1">&#x02212;&#x02009;15.8% (95% CI &#x02212;&#x02009;19.5 to &#x02212;&#x02009;12.0%)</td><td rowspan="1" colspan="1">&#x02212;&#x02009;5.4<xref ref-type="fn" rid="T3-F2"><sup>&#x02020;</sup></xref>
</td><td rowspan="1" colspan="1">&#x02212;&#x02009;6.6<xref ref-type="fn" rid="T3-F2"><sup>&#x02020;</sup></xref>
</td></tr><tr><td colspan="7" rowspan="1">
<italic>HDL cholesterol</italic>
</td></tr><tr><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">&#x02212;&#x02009;3.7 (0.8)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">no significant effects</td><td rowspan="1" colspan="1">no significant effects</td><td rowspan="1" colspan="1">5.1<xref ref-type="fn" rid="T3-F2"><sup>&#x02020;</sup></xref>
</td><td rowspan="1" colspan="1">5.9<xref ref-type="fn" rid="T3-F2"><sup>&#x02020;</sup></xref>
</td></tr><tr><td colspan="7" rowspan="1">
<italic>Triglycerides</italic>
</td></tr><tr><td rowspan="1" colspan="1">2 years</td><td rowspan="1" colspan="1">3.2 (3.1)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">8.0% (95% CI 1.5&#x02013;14.6%)</td><td rowspan="1" colspan="1">4.9% (95% CI &#x02212;&#x02009;2.2 to 11.9%)</td><td rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">13.6</td></tr></tbody></table><table-wrap-foot><fn><p>PEARL, Postmenopausal Evaluation And Risk-reduction with Lasofoxifene; LDL, low density lipoprotein; CI, confidence interval; HDL, high density lipoprotein</p></fn><fn id="T3-F1"><p>*, <italic>p</italic> &#x0003c;&#x02009;0.05 vs. placebo;</p></fn><fn id="T3-F2"><p><sup>&#x02020;</sup>, <italic>p</italic> &#x0003c;&#x02009;0.001 vs. placebo</p></fn></table-wrap-foot></table-wrap><p>Over 4 years of treatment in the MORE trial, there were no significant differences between RLX 60 or 120 mg or placebo in the incidence of endometrial hyperplasia or carcinoma (<xref ref-type="table" rid="T4">Table 4</xref>)<sup><xref ref-type="bibr" rid="CIT0038">38</xref></sup>. Endometrial thickness increased by 0.01 mm for women taking RLX 60 mg and decreased by 0.27 mm for women taking placebo (<italic>p</italic> &#x0003c;&#x02009;0.01 vs. placebo)<sup><xref ref-type="bibr" rid="CIT0038">38</xref></sup>. The incidence of endometrial polyps was higher in the RLX groups than in the placebo group (<italic>p</italic> =&#x02009;0.028) at 8 years in the MORE and CORE trials<sup><xref ref-type="bibr" rid="CIT0040">40</xref></sup>. In the MORE trial, the overall incidence of breast cancer was significantly reduced with both doses of RLX combined versus placebo (RR 0.4; 95% CI 0.2&#x02013;0.6; <italic>p</italic> &#x0003c;&#x02009;0.001)<sup><xref ref-type="bibr" rid="CIT0038">38</xref></sup>. In the CORE trial, RLX 60 mg reduced the incidence of invasive breast cancer and ER-positive breast cancer by 59% and by 66%, respectively<sup><xref ref-type="bibr" rid="CIT0039">39</xref></sup>. RLX has been shown to be as effective as tamoxifen in preventing invasive breast cancer in postmenopausal women in the Study of Tamoxifen And Raloxifene (STAR) trial (<italic>n</italic> =&#x02009;19 747)<sup><xref ref-type="bibr" rid="CIT0046">46</xref></sup>, but with a more favorable benefit/risk ratio for postmenopausal women with a uterus (<xref ref-type="table" rid="T4">Table 4</xref>)<sup><xref ref-type="bibr" rid="CIT0012">12</xref></sup>.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Incidence of endometrial and breast-related adverse events in phase-3 treatment studies of SERMs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">
<italic>Raloxifene</italic>
<break/>(MORE; <italic>n</italic> =&#x02009;7705)<sup><xref ref-type="bibr" rid="CIT0038">38</xref></sup>, (CORE; <italic>n</italic> =&#x02009;4011)<sup><xref ref-type="bibr" rid="CIT0040">40</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Lasofoxifene</italic>
<break/>PEARL (<italic>n</italic> =&#x02009;8556)<sup><xref ref-type="bibr" rid="CIT0047">47</xref>,<xref ref-type="bibr" rid="CIT0049">49</xref>,<xref ref-type="bibr" rid="CIT0050">50</xref></sup>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<italic>Bazedoxifene</italic>
<break/>(<italic>n</italic> =&#x02009;7492 and <italic>n</italic> =&#x02009;4216)<sup><xref ref-type="bibr" rid="CIT0054">54</xref>,<xref ref-type="bibr" rid="CIT0058">58</xref></sup>
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">
<italic>60 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>120 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.25 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>0.5 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>20 mg</italic>
</th><th align="center" rowspan="1" colspan="1">
<italic>40 mg</italic>
</th></tr></thead><tbody><tr><td colspan="7" rowspan="1">
<bold>Endometrial safety</bold>
</td></tr><tr><td colspan="7" rowspan="1">
<italic>Incidence of endometrial hyperplasia</italic>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">0.05% (for pooled RLX 60/120 mg)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.1%</td><td rowspan="1" colspan="1">0.1%</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.11%</td><td rowspan="1" colspan="1">0.07%</td><td rowspan="1" colspan="1">0.1%</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Incidence of endometrial cancer</italic>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">0.2%</td><td rowspan="1" colspan="1">&#x0003c;&#x02009;0.1%</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.1%</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.07%</td><td rowspan="1" colspan="1">0.07%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Incidence of endometrial neoplasia (polyps)</italic>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">0.6%</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">3.8%<xref ref-type="fn" rid="T4-F1">*</xref></td><td rowspan="1" colspan="1">4.0%<xref ref-type="fn" rid="T4-F1">*</xref></td><td rowspan="1" colspan="1">0.7%</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">8 years</td><td colspan="2" rowspan="1">3.2%<xref ref-type="fn" rid="T4-F2"><sup>&#x02020;</sup></xref>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="7" rowspan="1">
<italic>Change from baseline in endometrial thickness</italic> (mm)</td></tr><tr><td rowspan="1" colspan="1">2 years</td><td colspan="0" rowspan="1"/><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;0.07&#x02009;&#x000b1;&#x02009;0.11</td><td rowspan="1" colspan="1">0.10&#x02009;&#x000b1;&#x02009;0.12</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">0.01<xref ref-type="fn" rid="T4-F4">**</xref> (for pooled RLX 60/120 mg)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">1.19<xref ref-type="fn" rid="T4-F1">*</xref></td><td rowspan="1" colspan="1">1.43<xref ref-type="fn" rid="T4-F1">*</xref></td><td rowspan="1" colspan="1">&#x02013;0.05&#x02009;&#x000b1;&#x02009;0.13</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<bold>Breast safety</bold>
</td></tr><tr><td colspan="7" rowspan="1">
<italic>Overall incidence of breast cancer</italic>
<xref ref-type="fn" rid="T4-F3"><sup>&#x02021;</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">RR vs. placebo 0.35<xref ref-type="fn" rid="T4-F1">*</xref> (95% CI 0.21&#x02013;0.58) for pooled RLX 60/120 mg</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.3%</td><td rowspan="1" colspan="1">0.2%</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.73% (HR vs. placebo 0.82; 95% CI 0.45&#x02013;1.49)</td><td rowspan="1" colspan="1">0.18% (HR vs. placebo 0.21<xref ref-type="fn" rid="T4-F1">*</xref>; 95% CI 0.08&#x02013;0.55)</td><td rowspan="1" colspan="1">0.5%<xref ref-type="fn" rid="T4-F4">**</xref></td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Incidence of ER-positive breast cancer</italic>
<xref ref-type="fn" rid="T4-F3"><sup>&#x02021;</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">0.08% (RR vs. placebo 0.10; 95% CI 0.04&#x02013;0.24 for pooled RLX 60/120 mg)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.40% (HR vs. placebo 0.52; 95% CI 0.25&#x02013;1.08)</td><td rowspan="1" colspan="1">0.15% (HR vs. placebo 0.19<xref ref-type="fn" rid="T4-F1">*</xref>; 95% CI 0.07&#x02013;0.56)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="7" rowspan="1">
<italic>Incidence of invasive breast cancer</italic>
<xref ref-type="fn" rid="T4-F3"><sup>&#x02021;</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">3 years</td><td colspan="2" rowspan="1">0.25% (RR vs. placebo 0.24; 95% CI 0.13&#x02013;0.44 for pooled RLX 60/120 mg)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">5 years</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">0.59% (HR vs. placebo 0.79; 95% CI 0.41&#x02013;1.52)</td><td rowspan="1" colspan="1">0.11% (HR vs. placebo 0.15<xref ref-type="fn" rid="T4-F1">*</xref>; 95% CI 0.04&#x02013;0.50)</td><td rowspan="1" colspan="1">0.5%</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn><p>SERM, selective estrogen receptor modulator; MORE, Multiple Outcomes of Raloxifene Evaluation; CORE, Continuing Outcomes Relevant to Evista; PEARL, Postmenopausal Evaluation And Risk-reduction with Lasofoxifene; RLX, raloxifene; RR, relative risk; CI, confidence interval; HR, hazard ratio; ER, estrogen receptor</p></fn><fn id="T4-F1"><p>*, <italic>p</italic> &#x02264;&#x02009;0.001 vs. placebo;</p></fn><fn id="T4-F2"><p><sup>&#x02020;</sup>, <italic>p</italic> &#x0003c;&#x02009;0.05 vs. placebo;</p></fn><fn id="T4-F3"><p><sup>&#x02021;</sup>, RR and HR vs. placebo;</p></fn><fn id="T4-F4"><p>**, <italic>p</italic> &#x0003c;&#x02009;0.01 vs. placebo</p></fn></table-wrap-foot></table-wrap></sec><sec id="ss10"><title>Lasofoxifene</title><p>LAS 0.25 and 0.5 mg/day were evaluated in the phase-3, 5-year, Postmenopausal Evaluation and Risk-reduction with Lasofoxifene (PEARL) trial (<italic>n</italic> =&#x02009;8556)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>. PEARL enrolled postmenopausal women aged 59&#x02013;80 years with osteoporosis, defined as a lumbar spine or femoral neck BMD <italic>T</italic>-score of &#x02264; &#x02013;2.5.</p><p>Daily treatment over 3 years with LAS 0.25 and 0.5 mg was associated with significant reductions of 31% (HR 0.69; 95% CI 0.55&#x02013;0.87) and 42% (HR 0.58; 95% CI 0.45&#x02013;0.73), respectively, in the risk of vertebral fracture compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.01 for both). The significant reductions in vertebral fracture risk were maintained at 5 years (<italic>p</italic> &#x0003c;&#x02009;0.001 for both; <xref ref-type="table" rid="T1">Table 1</xref>)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>. LAS 0.5 mg (but not LAS 0.25 mg) also reduced the risk of non-vertebral fracture versus placebo at 5 years (<italic>p</italic> =&#x02009;0.002 for LAS 0.5 mg)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>.</p><p>Relative to placebo, lumbar spine BMD improved at 5 years in the PEARL trial by 3.0% with LAS 0.25 mg and by 3.1% with LAS 0.5 mg (<xref ref-type="table" rid="T1">Table 1</xref>)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>.</p><p>More women reported hot flushes in the LAS groups (<italic>n</italic> =&#x02009;372 (13.0%) and <italic>n</italic> =&#x02009;365 (12.8%) for LAS 0.25 and 0.5 mg, respectively) than in the placebo group (<italic>n</italic> =&#x02009;158 (5.5%); <italic>p</italic> &#x0003c;&#x02009;0.001 for both) over 5 years of treatment<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>.</p><p>An increased risk of VTE was seen with LAS 0.25 mg (HR 2.67; 95% CI 1.55&#x02013;4.58) and LAS 0.5 mg (HR 2.06; 95% CI 1.17&#x02013;3.61) compared with placebo (<italic>p</italic> =&#x02009;0.01 and <italic>p</italic> &#x0003c;&#x02009;0.001, respectively) at 5 years (<xref ref-type="table" rid="T2">Table 2</xref>)<sup><xref ref-type="bibr" rid="CIT0048">48</xref></sup>. In the same study, LAS 0.25 mg (HR 0.61; 95% CI 0.39&#x02013;0.96) and LAS 0.5 mg (HR 0.64; 95% CI 0.41&#x02013;0.99) decreased the risk of stroke compared with placebo. The risk of major coronary heart disease events was reduced by 32% with LAS 0.5 mg compared with placebo (HR 0.68; 95% CI 0.50&#x02013;0.93; <italic>p</italic> =&#x02009;0.02); the 24% decrease seen with LAS 0.25 mg was not statistically significant compared with placebo (HR 0.76; 95% CI 0.58&#x02013;1.03; <italic>p</italic> =&#x02009;0.08)<sup><xref ref-type="bibr" rid="CIT0048">48</xref></sup>.</p><p>Three years of treatment with LAS did not affect HDL cholesterol but was associated with a reduction in LDL cholesterol for LAS 0.25 and 0.5 mg. LAS 0.25 and 0.5 mg were associated with increases in triglycerides at 3 years (<xref ref-type="table" rid="T3">Table 3</xref>)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>.</p><p>There was a statistically significant increase in endometrial thickness from baseline for women treated with LAS 0.25 mg (1.19 mm) and LAS 0.5 mg (1.43 mg; <italic>p</italic> &#x0003c;&#x02009;0.001 vs. placebo), although the incidences of endometrial hyperplasia and endometrial carcinoma were not significantly different for LAS compared with placebo (<xref ref-type="table" rid="T4">Table 4</xref>)<sup><xref ref-type="bibr" rid="CIT0049">49</xref></sup>. A significantly higher proportion of women in the LAS 0.25-mg (7.2%) and LAS 0.5-mg (7.0%) groups required diagnostic uterine procedures based on clinical trial protocol requirements for reports of vaginal bleeding or transvaginal ultrasound abnormalities compared with those in the placebo group (2.7%; <italic>p</italic> =&#x02009;0.001)<sup><xref ref-type="bibr" rid="CIT0047">47</xref>,<xref ref-type="bibr" rid="CIT0049">49</xref></sup>. The incidence of uterine polyps was significantly higher with LAS 0.25 and 0.5 mg compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.001 for both); based on histologic results, all polyps seen in the LAS groups were associated with atrophic features<sup><xref ref-type="bibr" rid="CIT0049">49</xref></sup>. Overall, LAS 0.5 mg showed a 79% reduced risk of breast cancer versus placebo; the reduction in breast cancer risk was not significantly different between placebo and LAS 0.25 mg<sup><xref ref-type="bibr" rid="CIT0050">50</xref></sup>. LAS 0.5 mg was associated with an 85% reduced risk of invasive breast cancer versus placebo (<italic>p</italic> &#x0003c;&#x02009;0.001)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>. Although there was no difference in mortality between LAS 0.5 mg and placebo in the PEARL trial, there was a statistically significant increase in mortality with LAS 0.25 mg (90 deaths, 3.2%, 7.0 deaths per 1000 person-years) compared with placebo (65 deaths, 2.3%, 5.1 deaths per 1000 person-years; <italic>p</italic> =&#x02009;0.05). There was a trend toward more deaths due to cancer with LAS 0.25 mg (34 cases, 1.2%) than with placebo (20 cases, 0.7%; <italic>p</italic> =&#x02009;0.06)<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>.</p></sec><sec id="ss11"><title>Bazedoxifene</title><p>The pivotal phase-3 treatment study of BZA 20 and 40 mg/day versus RLX 60 mg and placebo was conducted in healthy postmenopausal women aged 55&#x02013;85 years (<italic>n</italic> =&#x02009;7492) with osteoporosis over 3 years<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>. Osteoporosis was defined as lumbar spine or femoral neck <italic>T</italic>-score between &#x02013;2.5 and &#x02013;4.0 for women without prevalent vertebral fracture, or <italic>T</italic>-score &#x02265; &#x02013;4.0 for women with prevalent vertebral fracture.</p><p>The incidence of new vertebral fractures with BZA 20 and 40 mg was significantly reduced by 42% (HR 0.58; 95% CI 0.38&#x02013;0.89) and 37% (HR 0.63; 95% CI 0.42&#x02013;0.96), respectively, and by 42% (HR 0.58; 95% CI 0.38&#x02013;0.89) with RLX 60 mg compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.05 for all; <xref ref-type="table" rid="T1">Table 1</xref>)<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>. There were no overall significant differences between BZA 20 or 40 mg, RLX 60 mg, or placebo in the incidence of non-vertebral fractures<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>. However, in a <italic>post hoc</italic> analysis of a subgroup of higher-risk women (baseline femoral neck BMD <italic>T</italic>-score &#x02264; &#x02013;3.0 and/or &#x02265;&#x02009;1 moderate or severe vertebral fracture or &#x02265;&#x02009;2 mild fractures; <italic>n</italic> =&#x02009;1772), BZA 20 mg was associated with a 50% reduction in non-vertebral fracture risk versus placebo (<italic>p</italic> =&#x02009;0.02) and a 44% reduction versus RLX 60 mg (<italic>p</italic> =&#x02009;0.05)<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>. The fracture data from the overall population were independently re-evaluated based on baseline fracture risk using the Fracture Risk Assessment Tool (FRAX<sup>&#x000ae;</sup>)<sup><xref ref-type="bibr" rid="CIT0052">52</xref>,<xref ref-type="bibr" rid="CIT0053">53</xref></sup>. Consistent with the results of the original <italic>post hoc</italic> subgroup analysis, the efficacy of BZA on non-vertebral, morphometric, and all clinical fractures was shown to increase with an increasing likelihood of fractures<sup><xref ref-type="bibr" rid="CIT0052">52</xref>,<xref ref-type="bibr" rid="CIT0053">53</xref></sup>. Specifically, BZA (based on combined data for the 20- and 40-mg doses) significantly decreased the risk of morphometric vertebral, clinical, and non-vertebral fractures for women at or above the 6.9%, 16.0%, and 20.0% probability thresholds, respectively<sup><xref ref-type="bibr" rid="CIT0052">52</xref>,<xref ref-type="bibr" rid="CIT0053">53</xref></sup>. These results suggest that women at higher risk of fracture are most likely to benefit from treatment with BZA<sup><xref ref-type="bibr" rid="CIT0052">52</xref></sup>.</p><p>BZA 20 and 40 mg and RLX 60 mg significantly improved changes in lumbar spine BMD from baseline by 2.21%, 2.38%, and 2.96%, respectively, compared with placebo (0.88%; <italic>p</italic> &#x0003c;&#x02009;0.001 vs. placebo for all) at 3 years (<xref ref-type="table" rid="T1">Table 1</xref>)<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>.</p><p>BZA 20 and 40 mg were generally safe and well tolerated, with an overall safety profile similar to those with RLX 60 mg and placebo<sup><xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0054">54</xref></sup>. The incidence of hot flushes was greater for women treated with BZA 20 mg (12.6%), BZA 40 mg (13.0%), and RLX 60 mg (12.0%) compared with placebo (6.3%; overall <italic>p</italic> &#x0003c;&#x02009;0.001)<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>.</p><p>The incidence of cardiovascular adverse events was generally low among groups<sup><xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0054">54</xref></sup>. There was a higher incidence of VTE with BZA 20 mg (HR 1.6; 95% CI 0.8&#x02013;3.94), BZA 40 mg (HR 1.7; 95% CI 0.70&#x02013;4.07), and RLX 60 mg (HR 1.1; 95% CI 0.44&#x02013;2.96) compared with placebo, primarily due to deep vein thromboses (<xref ref-type="table" rid="T2">Table 2</xref>). There was no difference in the incidence of stroke between placebo and BZA 20 and 40 mg or RLX 60 mg<sup><xref ref-type="bibr" rid="CIT0054">54</xref></sup>.</p><p>The reductions from baseline in total and LDL cholesterol for BZA 20 and 40 mg and RLX 60 mg were significantly greater compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.001 for all; <xref ref-type="table" rid="T3">Table 3</xref>). There were significant increases from baseline in HDL cholesterol for BZA 20 and 40 mg and RLX 60 mg compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.001) and no significant differences between groups in changes from baseline in triglycerides<sup><xref ref-type="bibr" rid="CIT0054">54</xref></sup>.</p><p>There were no significant differences in the incidence of endometrial hyperplasia or endometrial carcinoma among treatment groups (<xref ref-type="table" rid="T4">Table 4</xref>). At 1 year, there was a significant increase from baseline in endometrial thickness for RLX 60 mg (0.32 mm) compared with placebo (&#x02013;0.11 mm; <italic>p</italic> =&#x02009;0.010), which was not seen with BZA 20 mg (0.11 mm) or BZA 40 mg (&#x02013;0.01 mm)<sup><xref ref-type="bibr" rid="CIT0055">55</xref></sup>. There were no significant differences from baseline in endometrial thickness for BZA 20 or 40 mg, RLX 60 mg, or placebo at 2 years<sup><xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0054">54</xref></sup>. The incidence of endometrial neoplasia (polyps) was not significantly different for BZA 20 or 40 mg, RLX 60 mg, or placebo at 3 years<sup><xref ref-type="bibr" rid="CIT0054">54</xref></sup>. There were numerically fewer cases of breast cancer in the BZA groups (<italic>n</italic> =&#x02009;6 for BZA 20 mg and <italic>n</italic> =&#x02009;4 for BZA 40 mg) than in the RLX 60 mg group (<italic>n</italic> =&#x02009;7) or the placebo group (<italic>n</italic> =&#x02009;8); the differences were not statistically significant<sup><xref ref-type="bibr" rid="CIT0054">54</xref>,<xref ref-type="bibr" rid="CIT0055">55</xref></sup>.</p><p>In a 2-year extension (<italic>n</italic> =&#x02009;4216) of the core treatment study (years 4&#x02013;5), the RLX 60-mg arm was discontinued and subjects receiving BZA 40 mg were transitioned to BZA 20 mg (BZA 40/20 mg) during year 4. In a second 2-year extension (years 6&#x02013;7; <italic>n</italic> =&#x02009;1732), all subjects continued to receive BZA 20 mg or placebo<sup><xref ref-type="bibr" rid="CIT0056">56</xref>,<xref ref-type="bibr" rid="CIT0057">57</xref></sup>. The efficacy of BZA 20 mg on vertebral fractures was sustained through 5 and 7 years<sup><xref ref-type="bibr" rid="CIT0056">56</xref>,<xref ref-type="bibr" rid="CIT0057">57</xref></sup>. At 5 years, the risk of new vertebral fracture was reduced by 35% and 40% compared with placebo for BZA 20 mg and BZA 40/20 mg, respectively (<italic>p</italic> &#x0003c;&#x02009;0.05 vs. placebo for both)<sup><xref ref-type="bibr" rid="CIT0056">56</xref></sup>. Non-vertebral fracture incidence was not different among groups in the overall population at 5 or 7 years. In the higher-risk subgroup, the reduction in the risk of non-vertebral fracture with BZA 20 mg was 37% versus placebo (<italic>p</italic> =&#x02009;0.06) at 5 years; combined BZA data showed a 34% reduction versus placebo (<italic>p</italic> =&#x02009;0.05)<sup><xref ref-type="bibr" rid="CIT0056">56</xref></sup>. The safety and tolerability profiles of BZA at 5 and 7 years were generally consistent with those at 3 years<sup><xref ref-type="bibr" rid="CIT0057">57</xref>,<xref ref-type="bibr" rid="CIT0058">58</xref></sup>.</p></sec><sec id="ss12"><title>Bazedoxifene/conjugated estrogens</title><p>BZA paired with CE is a tissue selective estrogen complex being evaluated for the treatment of menopausal symptoms and the prevention of postmenopausal osteoporosis. In the 2-year, phase-3, Selective estrogens, Menopause, And Response to Therapy (SMART)-1 trial (<italic>n</italic> =&#x02009;3397)<sup><xref ref-type="bibr" rid="CIT0059 CIT0060 CIT0061 CIT0062">59&#x02013;62</xref></sup> of postmenopausal women with a uterus, BZA 20 mg/CE 0.45 and 0.625 mg significantly increased lumbar spine BMD and reduced bone turnover marker levels compared with placebo (<italic>p</italic> &#x0003c;&#x02009;0.001 for all) and showed low rates of endometrial hyperplasia in postmenopausal women with a uterus<sup><xref ref-type="bibr" rid="CIT0059">59</xref>,<xref ref-type="bibr" rid="CIT0061">61</xref></sup>. In subgroups of symptomatic women, BZA 20 mg/CE 0.45 and 0.625 mg significantly reduced the number and severity of hot flushes and improved measures of vulvar/vaginal atrophy<sup><xref ref-type="bibr" rid="CIT0060">60</xref></sup>. BZA 20 mg/CE 0.45 and 0.625 mg have also been associated with high rates of amenorrhea<sup><xref ref-type="bibr" rid="CIT0062">62</xref></sup>. In a larger study of symptomatic postmenopausal women with moderate-to-severe hot flushes (SMART-2; <italic>n</italic> =&#x02009;318), BZA 20 mg/CE 0.45 and 0.625 mg significantly reduced the number and severity of hot flushes over 12 weeks<sup><xref ref-type="bibr" rid="CIT0063">63</xref></sup>. BZA 20 mg/CE 0.45 and 0.625 mg were also effective in treating postmenopausal women with moderate-to-severe vulvar/vaginal atrophy over 12 weeks (SMART-3; <italic>n</italic> =&#x02009;652)<sup><xref ref-type="bibr" rid="CIT0064">64</xref></sup>. In all three SMART trials, the incidences of adverse events were low and similar between BZA/CE and placebo<sup><xref ref-type="bibr" rid="CIT0060">60</xref>,<xref ref-type="bibr" rid="CIT0063">63</xref>,<xref ref-type="bibr" rid="CIT0064">64</xref></sup>.</p></sec></sec><sec id="ss13"><title>THE ROLE OF SERMs IN THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS</title><p>Currently approved pharmacologic treatment options for osteoporosis include bisphosphonates, hormone therapy, parathyroid hormone, calcitonin, strontium ranelate (outside of North America), denosumab, and SERMs<sup><xref ref-type="bibr" rid="CIT0065 CIT0066 CIT0067">65&#x02013;67</xref></sup>. Bisphosphonates are considered the first-line treatment for postmenopausal osteoporosis, with demonstrated efficacy in reducing the incidence of vertebral fracture and, for risedronate and zoledronic acid, non-vertebral fracture<sup><xref ref-type="bibr" rid="CIT0065">65</xref></sup>. Bisphosphonates have also shown significant improvements in BMD of the spine and hip<sup><xref ref-type="bibr" rid="CIT0065">65</xref></sup>. However, bisphosphonates may be associated with safety and tolerability issues such as gastrointestinal intolerability (oral formulations)<sup><xref ref-type="bibr" rid="CIT0068">68</xref></sup> and acute-phase reaction symptoms (intravenous formulations)<sup><xref ref-type="bibr" rid="CIT0069">69</xref>,<xref ref-type="bibr" rid="CIT0070">70</xref></sup>. Concerns related to long-term treatment include the potential for atypical fractures<sup><xref ref-type="bibr" rid="CIT0071">71</xref></sup>, risk of osteonecrosis of the jaw<sup><xref ref-type="bibr" rid="CIT0072 CIT0073 CIT0074">72&#x02013;74</xref></sup>, and excessive suppression of bone turnover<sup><xref ref-type="bibr" rid="CIT0075">75</xref></sup>. In contrast to bisphosphonates that inhibit osteoclast activity<sup><xref ref-type="bibr" rid="CIT0075">75</xref></sup>, SERMs behave similar to estrogens in bone and may therefore be considered to be more physiological in action. SERMs may be an appropriate option for women who cannot tolerate bisphosphonates or for younger women at higher risk of fracture who will be treated for many years and are concerned about the long-term safety of bisphosphonates. The combination of SERMs and estrogens may be an option for women at increased risk of fracture who are still experiencing vasomotor symptoms. Sequential treatment for osteoporosis may be individualized by using both a SERM and a bisphosphonate at different points throughout a woman's lifetime. For such a treatment strategy, the well-established, long-term safety profile of SERMs (8 years of follow-up for RLX, 7 years of follow-up for BZA) is reassuring.</p></sec><sec sec-type="conclusions" id="ss14"><title>CONCLUSIONS</title><p>Over the years, SERMs have evolved toward the goal of an &#x02018;ideal&#x02019; SERM, an agent that has positive effects on the skeleton, cardiovascular system (e.g. lipid profile), and central nervous system without stimulation of breast or uterine tissue. The preclinical profiles of individual SERMs demonstrate variable effects on bone, uterine tissue, and breast tissue. BZA has been shown to be effective in preserving bone mass at low doses<sup><xref ref-type="bibr" rid="CIT0003">3</xref></sup>. Compared with LAS, BZA has demonstrated reduced mammary stimulation and no evidence of uterine stimulation<sup><xref ref-type="bibr" rid="CIT0033">33</xref>,<xref ref-type="bibr" rid="CIT0034">34</xref></sup>.</p><p>Historically, the majority of preclinical results have generally been predictive of clinical findings. In phase-3 clinical trials, RLX, LAS, and BZA have all shown significant reductions in the risk of vertebral fracture, increases in BMD, and reductions in markers of bone turnover<sup><xref ref-type="bibr" rid="CIT0037">37</xref>,<xref ref-type="bibr" rid="CIT0047">47</xref>,<xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0056">56</xref>,<xref ref-type="bibr" rid="CIT0076">76</xref></sup>. The incidence of non-vertebral fractures with RLX 60 mg was similar to that with placebo in the overall population<sup><xref ref-type="bibr" rid="CIT0037">37</xref></sup>; a significant reduction with RLX 60 mg was only seen in a population of women with the most severe prevalent fractures at baseline<sup><xref ref-type="bibr" rid="CIT0043">43</xref></sup>. A small and clinically irrelevant increase in endometrial thickness was seen with RLX 60 mg compared with placebo, but there was no effect on endometrial carcinoma or hyperplasia. The incidence of non-vertebral fractures was only significantly reduced with LAS 0.5 mg compared with placebo at 5 years in the overall population<sup><xref ref-type="bibr" rid="CIT0047">47</xref></sup>. Some endometrial safety findings with LAS include a small but significant increase in endometrial thickness and an increased incidence of endometrial polyps<sup><xref ref-type="bibr" rid="CIT0047">47</xref>,<xref ref-type="bibr" rid="CIT0049">49</xref></sup>. BZA 20 mg has shown a significant reduction in the risk of non-vertebral fractures compared with placebo and RLX 60 mg in a <italic>post hoc</italic> analysis of a subgroup of women at higher risk of fracture (baseline femoral neck BMD <italic>T</italic>-score &#x02264; &#x02013;3.0 and/or at least one moderate or severe vertebral fracture or at least two mild fractures)<sup><xref ref-type="bibr" rid="CIT0051">51</xref></sup>. There were no increases in endometrial hyperplasia, carcinoma, or thickness with BZA compared with placebo<sup><xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0054">54</xref>,<xref ref-type="bibr" rid="CIT0058">58</xref></sup>. VTE and hot flushes are class effects that have been associated with all SERMs<sup><xref ref-type="bibr" rid="CIT0038">38</xref>,<xref ref-type="bibr" rid="CIT0047">47</xref>,<xref ref-type="bibr" rid="CIT0048">48</xref>,<xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0054">54</xref></sup>. Finally, recently postmenopausal women at increased risk of fracture who also have vasomotor symptoms may benefit from treatment with BZA/CE, which has been shown to significantly increase BMD and also substantially decrease the incidence of hot flushes.</p><p>Over the years, SERMs have evolved to secure a place in osteoporosis therapy for postmenopausal women. They may be considered as options for women who cannot take or do not wish to take bisphosphonates, for younger women at increased risk of fracture and potentially breast cancer, who expect to remain on treatment for many years, or as part of long-term sequential interventions.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>Medical writing support for this manuscript was provided by Katie Gersh, PhD, of MedErgy and was funded by Pfizer Inc. The author was not compensated and retained full editorial control over the content of the article.</p><p>
<italic>Conflict of interest</italic> Dr Hadji has received unrestricted educational grants, honoraria, and research funding from Amgen, Astra Zeneca, Daichii Sankyo, Eli Lilly, GSK, Pfizer Inc, Novartis, and Roche.</p><p>
<italic>Source of funding</italic> Medical writing support for this manuscript was provided by Katie Gersh, PhD, of MedErgy and was funded by Pfizer Inc.</p></ack><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>MW</given-names></name></person-group><article-title>The role of selective estrogen receptor modulators (SERMs) in postmenopausal health</article-title><source>Ann NY Acad Sci</source><year>2003</year><volume>997</volume><fpage>373</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14644844</pub-id></element-citation></ref><ref id="CIT0002"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Lyttle</surname><given-names>CR</given-names></name></person-group><article-title>Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation</article-title><source>Ann NY Acad Sci</source><year>2001</year><volume>949</volume><fpage>317</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">11795370</pub-id></element-citation></ref><ref id="CIT0003"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Kharode</surname><given-names>YP</given-names></name><name><surname>Bodine</surname><given-names>PV</given-names></name><name><surname>Harris</surname><given-names>HA</given-names></name><name><surname>Miller</surname><given-names>CP</given-names></name><name><surname>Lyttle</surname><given-names>CR</given-names></name></person-group><article-title>Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>3999</fpage><lpage>4008</lpage><pub-id pub-id-type="pmid">15961563</pub-id></element-citation></ref><ref id="CIT0004"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostlund</surname><given-names>H</given-names></name><name><surname>Keller</surname><given-names>E</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name></person-group><article-title>Estrogen receptor gene expression in relation to neuropsychiatric disorders</article-title><source>Ann NY Acad Sci</source><year>2003</year><volume>1007</volume><fpage>54</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">14993040</pub-id></element-citation></ref><ref id="CIT0005"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>G</given-names></name><name><surname>El-Alfy</surname><given-names>M</given-names></name></person-group><article-title>Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs</article-title><source>J Clin Endocrinol Metab</source><year>2000</year><volume>85</volume><fpage>4835</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11134151</pub-id></element-citation></ref><ref id="CIT0006"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusec</surname><given-names>V</given-names></name><name><surname>Virdi</surname><given-names>AS</given-names></name><name><surname>Prince</surname><given-names>R</given-names></name><name><surname>Triffitt</surname><given-names>JT</given-names></name></person-group><article-title>Localization of estrogen receptor-alpha in human and rabbit skeletal tissues</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><fpage>2421</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9661622</pub-id></element-citation></ref><ref id="CIT0007"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>O</given-names></name><name><surname>Kindblom</surname><given-names>LG</given-names></name><name><surname>Ohlsson</surname><given-names>C</given-names></name></person-group><article-title>Expression and localization of estrogen receptor-beta in murine and human bone</article-title><source>J Bone Miner Res</source><year>1999</year><volume>14</volume><fpage>923</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10352100</pub-id></element-citation></ref><ref id="CIT0008"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>GG</given-names></name><name><surname>Carlsson</surname><given-names>B</given-names></name><name><surname>Grandien</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta</article-title><source>Endocrinology</source><year>1997</year><volume>138</volume><fpage>863</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">9048584</pub-id></element-citation></ref><ref id="CIT0009"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Roughton</surname><given-names>M</given-names></name><name><surname>Forsyth</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1657</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21422412</pub-id></element-citation></ref><ref id="CIT0010"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JM</given-names></name><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>Selective estrogen receptor modulators: from bench, to bedside, and back again</article-title><source>Menopausal Med</source><year>2008</year><volume>16</volume><fpage>S1</fpage><lpage>6</lpage></element-citation></ref><ref id="CIT0011"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><etal>et al</etal></person-group><article-title>Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><fpage>1371</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">9747868</pub-id></element-citation></ref><ref id="CIT0012"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>AN</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Gail</surname><given-names>MH</given-names></name><etal>et al</etal></person-group><article-title>Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>2327</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21537036</pub-id></element-citation></ref><ref id="CIT0013"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powles</surname><given-names>TJ</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Tidy</surname><given-names>A</given-names></name><name><surname>Ashley</surname><given-names>S</given-names></name></person-group><article-title>Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">8558225</pub-id></element-citation></ref><ref id="CIT0014"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooke</surname><given-names>AL</given-names></name><name><surname>Metge</surname><given-names>C</given-names></name><name><surname>Lix</surname><given-names>L</given-names></name><name><surname>Prior</surname><given-names>HJ</given-names></name><name><surname>Leslie</surname><given-names>WD</given-names></name></person-group><article-title>Tamoxifen use and osteoporotic fracture risk: a population-based analysis</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>5227</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">18838712</pub-id></element-citation></ref><ref id="CIT0015"><label>15.</label><element-citation publication-type="journal"><collab>American College of Obstetricians and Gynecologists</collab><article-title>ACOG committee opinion: Tamoxifen and endometrial cancer</article-title><source>Int J Gynaecol Obstet</source><year>2001</year><volume>73</volume><fpage>77</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11411456</pub-id></element-citation></ref><ref id="CIT0016"><label>16.</label><element-citation publication-type="book"><collab>EVISTA</collab><source>(raloxifene hydrochloride) tablet for oral use [package insert]</source><publisher-loc>Indianapolis, IN</publisher-loc><publisher-name>Eli Lilly and Company</publisher-name><year>2008</year></element-citation></ref><ref id="CIT0017"><label>17.</label><element-citation publication-type="journal"><collab>European Medicines Agency</collab><article-title>European Public Assessment Report (EPAR)</article-title><source>EVISTA. EPAR summary for the public</source><italic><ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000184/WC500031005.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000184/WC500031005.pdf</ext-link></italic></element-citation></ref><ref id="CIT0018"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grady</surname><given-names>D</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Stock</surname><given-names>JL</given-names></name><etal>et al</etal></person-group><article-title>Effect of raloxifene on all-cause mortality</article-title><source>Am J Med</source><year>2010</year><volume>123</volume><fpage>469</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20399327</pub-id></element-citation></ref><ref id="CIT0019"><label>19.</label><element-citation publication-type="book"><collab>FABLYN</collab><source>(lasofoxifene) tablet for oral use [package insert]</source><publisher-loc>Kent, UK</publisher-loc><publisher-name>Pfizer, Limited</publisher-name><year>2009</year></element-citation></ref><ref id="CIT0020"><label>20.</label><element-citation publication-type="journal"><collab>Pfizer</collab><source>CONBRIZA 20 mg film-coated tablets Summary of Product Characteristics</source><fpage>2011</fpage></element-citation></ref><ref id="CIT0021"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>DP</given-names></name></person-group><article-title>The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>871</fpage><lpage>7s</lpage></element-citation></ref><ref id="CIT0022"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrodin</surname><given-names>TJ</given-names></name><name><surname>Chang</surname><given-names>KC</given-names></name><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Freedman</surname><given-names>LP</given-names></name><name><surname>Nagpal</surname><given-names>S</given-names></name></person-group><article-title>Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene&#x02013;conjugated estrogens combination</article-title><source>Mol Endocrinol</source><year>2009</year><volume>23</volume><fpage>75</fpage><lpage>85</lpage></element-citation></ref><ref id="CIT0023"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>BL</given-names></name><name><surname>Hartmann</surname><given-names>LC</given-names></name></person-group><article-title>Selective estrogen-receptor modulators &#x02013; mechanisms of action and application to clinical practice</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>618</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">12584371</pub-id></element-citation></ref><ref id="CIT0024"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taranta</surname><given-names>A</given-names></name><name><surname>Brama</surname><given-names>M</given-names></name><name><surname>Teti</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro</article-title><source>Bone</source><year>2002</year><volume>30</volume><fpage>368</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">11856644</pub-id></element-citation></ref><ref id="CIT0025"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofbauer</surname><given-names>LC</given-names></name><name><surname>Kuhne</surname><given-names>CA</given-names></name><name><surname>Viereck</surname><given-names>V</given-names></name></person-group><article-title>The OPG/RANKL/RANK system in metabolic bone diseases</article-title><source>J Musculoskelet Neuronal Interact</source><year>2004</year><volume>4</volume><fpage>268</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">15615494</pub-id></element-citation></ref><ref id="CIT0026"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>CH</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Bryant</surname><given-names>HU</given-names></name></person-group><article-title>Raloxifene preserves bone strength and bone mass in ovariectomized rats</article-title><source>Endocrinology</source><year>1994</year><volume>135</volume><fpage>2001</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7956922</pub-id></element-citation></ref><ref id="CIT0027"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Rippy</surname><given-names>MK</given-names></name><name><surname>Bryant</surname><given-names>HU</given-names></name></person-group><article-title>Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats</article-title><source>FASEB J</source><year>1996</year><volume>10</volume><fpage>905</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">8666168</pub-id></element-citation></ref><ref id="CIT0028"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzano</surname><given-names>MA</given-names></name><name><surname>Peer</surname><given-names>CW</given-names></name><name><surname>Smith</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid</article-title><source>J Natl Cancer Inst</source><year>1996</year><volume>88</volume><fpage>123</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8537973</pub-id></element-citation></ref><ref id="CIT0029"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>HZ</given-names></name><name><surname>Foley</surname><given-names>GL</given-names></name><name><surname>Simmons</surname><given-names>HA</given-names></name><name><surname>Shen</surname><given-names>V</given-names></name><name><surname>Thompson</surname><given-names>DD</given-names></name></person-group><article-title>Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats</article-title><source>Endocrinology</source><year>2004</year><volume>145</volume><fpage>1996</fpage><lpage>2005</lpage><pub-id pub-id-type="pmid">14726439</pub-id></element-citation></ref><ref id="CIT0030"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>LA</given-names></name><name><surname>Pittman</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>CX</given-names></name><name><surname>Aliaga</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Moyer</surname><given-names>JD</given-names></name></person-group><article-title>LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>8683</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11751385</pub-id></element-citation></ref><ref id="CIT0031"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharode</surname><given-names>Y</given-names></name><name><surname>Bodine</surname><given-names>PV</given-names></name><name><surname>Miller</surname><given-names>CP</given-names></name><name><surname>Lyttle</surname><given-names>CR</given-names></name><name><surname>Komm</surname><given-names>BS</given-names></name></person-group><article-title>The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention</article-title><source>Endocrinology</source><year>2008</year><volume>149</volume><fpage>6084</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">18703623</pub-id></element-citation></ref><ref id="CIT0032"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Vlasseros</surname><given-names>F</given-names></name><name><surname>Samadfam</surname><given-names>R</given-names></name><name><surname>Chouinard</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>SY</given-names></name></person-group><article-title>Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats</article-title><source>Bone</source><year>2011</year><volume>49</volume><fpage>376</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">21658483</pub-id></element-citation></ref><ref id="CIT0033"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crabtree</surname><given-names>JS</given-names></name><name><surname>Peano</surname><given-names>BJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Winneker</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>HA</given-names></name></person-group><article-title>Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland</article-title><source>Mol Cell Endocrinol</source><year>2008</year><volume>287</volume><fpage>40</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18367319</pub-id></element-citation></ref><ref id="CIT0034"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peano</surname><given-names>BJ</given-names></name><name><surname>Crabtree</surname><given-names>JS</given-names></name><name><surname>Komm</surname><given-names>BS</given-names></name><name><surname>Winneker</surname><given-names>RC</given-names></name><name><surname>Harris</surname><given-names>HA</given-names></name></person-group><article-title>Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland</article-title><source>Endocrinology</source><year>2009</year><volume>150</volume><fpage>1897</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">19022889</pub-id></element-citation></ref><ref id="CIT0035"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis-Wambi</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name><name><surname>Curpan</surname><given-names>R</given-names></name><name><surname>Grigg</surname><given-names>R</given-names></name><name><surname>Sarker</surname><given-names>MA</given-names></name><name><surname>Jordan</surname><given-names>VC</given-names></name></person-group><article-title>The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and downregulates estrogen receptor &#x003b1; and cyclin D1</article-title><source>Mol Pharmacol</source><year>2011</year><volume>80</volume><fpage>610</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">21737572</pub-id></element-citation></ref><ref id="CIT0036"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>KCN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bodine</surname><given-names>PV</given-names></name><name><surname>Nagpal</surname><given-names>S</given-names></name><name><surname>Komm</surname><given-names>BS</given-names></name></person-group><article-title>Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens</article-title><source>J Steroid Biochem Mol Biol</source><year>2010</year><volume>118</volume><fpage>117</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19914376</pub-id></element-citation></ref><ref id="CIT0037"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ettinger</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Mitlak</surname><given-names>BH</given-names></name><etal>et al</etal></person-group><article-title>Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial</article-title><source>JAMA</source><year>1999</year><volume>282</volume><fpage>637</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">10517716</pub-id></element-citation></ref><ref id="CIT0038"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Eckert</surname><given-names>S</given-names></name><name><surname>Krueger</surname><given-names>KA</given-names></name><etal>et al</etal></person-group><article-title>The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation</article-title><source>JAMA</source><year>1999</year><volume>281</volume><fpage>2189</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">10376571</pub-id></element-citation></ref><ref id="CIT0039"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>S</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene</article-title><source>J Natl Cancer Inst</source><year>2004</year><volume>96</volume><fpage>1751</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">15572757</pub-id></element-citation></ref><ref id="CIT0040"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martino</surname><given-names>S</given-names></name><name><surname>Disch</surname><given-names>D</given-names></name><name><surname>Dowsett</surname><given-names>SA</given-names></name><name><surname>Keech</surname><given-names>CA</given-names></name><name><surname>Mershon</surname><given-names>JL</given-names></name></person-group><article-title>Safety assessment of raloxifene over eight years in a clinical trial setting</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>1441</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16197663</pub-id></element-citation></ref><ref id="CIT0041"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siris</surname><given-names>ES</given-names></name><name><surname>Harris</surname><given-names>ST</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study</article-title><source>J Bone Miner Res</source><year>2005</year><volume>20</volume><fpage>1514</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">16059623</pub-id></element-citation></ref><ref id="CIT0042"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name><etal>et al</etal></person-group><article-title>Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial</article-title><source>Bone</source><year>2003</year><volume>33</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">13678769</pub-id></element-citation></ref><ref id="CIT0043"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Genant</surname><given-names>HK</given-names></name><name><surname>Crans</surname><given-names>GG</given-names></name><etal>et al</etal></person-group><article-title>Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial</article-title><source>Bone</source><year>2003</year><volume>33</volume><fpage>522</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">14555255</pub-id></element-citation></ref><ref id="CIT0044"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Mosca</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>125</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16837676</pub-id></element-citation></ref><ref id="CIT0045"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Bjarnason</surname><given-names>NH</given-names></name><name><surname>Mitlak</surname><given-names>BH</given-names></name><etal>et al</etal></person-group><article-title>Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><fpage>1641</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9385122</pub-id></element-citation></ref><ref id="CIT0046"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>VG</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><etal>et al</etal></person-group><article-title>Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>2727</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16754727</pub-id></element-citation></ref><ref id="CIT0047"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Ensrud</surname><given-names>K</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name><etal>et al</etal></person-group><article-title>Lasofoxifene in postmenopausal women with osteoporosis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>686</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">20181970</pub-id></element-citation></ref><ref id="CIT0048"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ensrud</surname><given-names>K</given-names></name><name><surname>LaCroix</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>1716</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">20937977</pub-id></element-citation></ref><ref id="CIT0049"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>SR</given-names></name><name><surname>Neven</surname><given-names>P</given-names></name><name><surname>Cummings</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Postmenopausal evaluation and risk reduction with lasofoxifene trial: 5-year gynecological outcomes</article-title><source>Menopause</source><year>2010</year><volume>18</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20689465</pub-id></element-citation></ref><ref id="CIT0050"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaCroix</surname><given-names>AZ</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name><etal>et al</etal></person-group><article-title>Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women</article-title><source>J Natl Cancer Inst</source><year>2010</year><volume>102</volume><fpage>1706</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">21051656</pub-id></element-citation></ref><ref id="CIT0051"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>SL</given-names></name><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Genant</surname><given-names>HK</given-names></name><etal>et al</etal></person-group><article-title>Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial</article-title><source>J Bone Miner Res</source><year>2008</year><volume>23</volume><fpage>1923</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">18665787</pub-id></element-citation></ref><ref id="CIT0052"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>McCloskey</surname><given-names>EV</given-names></name></person-group><article-title>Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX</article-title><source>Bone</source><year>2009</year><volume>44</volume><fpage>1049</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">19254788</pub-id></element-citation></ref><ref id="CIT0053"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCloskey</surname><given-names>E</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Chines</surname><given-names>A</given-names></name><name><surname>Kanis</surname><given-names>J</given-names></name></person-group><article-title>Assessment of the effect of bazedoxifene on non-vertebral fracture risk</article-title><source>J Bone Miner Res</source><volume>24</volume><issue>(Suppl 1)</issue><ext-link ext-link-type="uri" xlink:href="http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=&#x02009;6c55b263&#x02013;692e-4a37-b807-f7a153641564">http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=&#x02009; 6c55b263&#x02013;692e-4a37-b807-f7a153641564</ext-link><year>2010</year></element-citation></ref><ref id="CIT0054"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Chesnut</surname><given-names>CH</given-names><suffix>III</suffix></name><name><surname>Adachi</surname><given-names>JD</given-names></name><etal>et al</etal></person-group><article-title>Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis</article-title><source>BMC Musculoskelet Disord</source><year>2010</year><volume>11</volume><fpage>130</fpage><pub-id pub-id-type="pmid">20569451</pub-id></element-citation></ref><ref id="CIT0055"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>DF</given-names></name><name><surname>Pinkerton</surname><given-names>JV</given-names></name><name><surname>Utian</surname><given-names>WH</given-names></name><etal>et al</etal></person-group><article-title>Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women</article-title><source>Menopause</source><year>2009</year><volume>16</volume><fpage>1109</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">19543129</pub-id></element-citation></ref><ref id="CIT0056"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>SL</given-names></name><name><surname>Chines</surname><given-names>AA</given-names></name><name><surname>Kendler</surname><given-names>DL</given-names></name><etal>et al</etal></person-group><article-title>Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study</article-title><source>Osteoporos Int</source><year>2012</year><volume>23</volume><fpage>351</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">21779819</pub-id></element-citation></ref><ref id="CIT0057"><label>57.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>S</given-names></name><name><surname>Silverman</surname><given-names>S</given-names></name><name><surname>Levine</surname><given-names>AB</given-names></name><etal>et al</etal></person-group><article-title>Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study</article-title><source>Presented at the 13th International Menopause Society World Congress on Menopause</source><month>6</month><day>8&#x02013;11</day><year>2011</year><publisher-loc>Rome, Italy</publisher-loc><publisher-name>Climacteric</publisher-name><year>2011</year><volume>14</volume><fpage>59</fpage></element-citation></ref><ref id="CIT0058"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Villiers</surname><given-names>TJ</given-names></name><name><surname>Chines</surname><given-names>AA</given-names></name><name><surname>Palacios</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial</article-title><source>Osteoporos Int</source><year>2011</year><volume>22</volume><fpage>567</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">20535606</pub-id></element-citation></ref><ref id="CIT0059"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>R</given-names></name><name><surname>Gallagher</surname><given-names>JC</given-names></name><name><surname>Kagan</surname><given-names>R</given-names></name><name><surname>Pickar</surname><given-names>JH</given-names></name><name><surname>Constantine</surname><given-names>G</given-names></name></person-group><article-title>Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>1045</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">19635616</pub-id></element-citation></ref><ref id="CIT0060"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>RA</given-names></name><name><surname>Pinkerton</surname><given-names>JV</given-names></name><name><surname>Gass</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>1025</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">19635615</pub-id></element-citation></ref><ref id="CIT0061"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickar</surname><given-names>JH</given-names></name><name><surname>Yeh</surname><given-names>I-T</given-names></name><name><surname>Bachmann</surname><given-names>G</given-names></name><name><surname>Speroff</surname><given-names>L</given-names></name></person-group><article-title>Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>1018</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19635613</pub-id></element-citation></ref><ref id="CIT0062"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>DF</given-names></name><name><surname>Lewis</surname><given-names>V</given-names></name><name><surname>Carr</surname><given-names>BR</given-names></name><name><surname>Olivier</surname><given-names>S</given-names></name><name><surname>Pickar</surname><given-names>JH</given-names></name></person-group><article-title>Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>1039</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">19635614</pub-id></element-citation></ref><ref id="CIT0063"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinkerton</surname><given-names>JV</given-names></name><name><surname>Utian</surname><given-names>WH</given-names></name><name><surname>Constantine</surname><given-names>GD</given-names></name><name><surname>Olivier</surname><given-names>S</given-names></name><name><surname>Pickar</surname><given-names>JH</given-names></name></person-group><article-title>Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial</article-title><source>Menopause</source><year>2009</year><volume>16</volume><fpage>1116</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19546826</pub-id></element-citation></ref><ref id="CIT0064"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagan</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>RS</given-names></name><name><surname>Pan</surname><given-names>K</given-names></name><name><surname>Mirkin</surname><given-names>S</given-names></name><name><surname>Pickar</surname><given-names>JH</given-names></name></person-group><article-title>A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women</article-title><source>Menopause</source><year>2010</year><volume>17</volume><fpage>281</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19779382</pub-id></element-citation></ref><ref id="CIT0065"><label>65.</label><element-citation publication-type="journal"><collab>North American Menopause Society</collab><article-title>Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society</article-title><source>Menopause</source><year>2010</year><volume>17</volume><fpage>25</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">20061894</pub-id></element-citation></ref><ref id="CIT0066"><label>66.</label><element-citation publication-type="book"><collab>Prolia</collab><source>(denosumab), injection, for subcutaneous use [package insert]</source><publisher-loc>Thousand Oaks, CA</publisher-loc><publisher-name>Amgen Inc</publisher-name><year>2010</year></element-citation></ref><ref id="CIT0067"><label>67.</label><element-citation publication-type="book"><collab>Prolia</collab><source>(denosumab) solution for injection [package insert]</source><publisher-loc>The Netherlands</publisher-loc><publisher-name>Amgen Europe BV</publisher-name><year>2010</year></element-citation></ref><ref id="CIT0068"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>C</given-names></name><name><surname>Newberry</surname><given-names>S</given-names></name><name><surname>Maglione</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>197</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">18087050</pub-id></element-citation></ref><ref id="CIT0069"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>DM</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>1809</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17476007</pub-id></element-citation></ref><ref id="CIT0070"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bobba</surname><given-names>RS</given-names></name><name><surname>Beattie</surname><given-names>K</given-names></name><name><surname>Parkinson</surname><given-names>B</given-names></name><name><surname>Kumbhare</surname><given-names>D</given-names></name><name><surname>Adachi</surname><given-names>JD</given-names></name></person-group><article-title>Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease</article-title><source>Drug Saf</source><year>2006</year><volume>29</volume><fpage>1133</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17147460</pub-id></element-citation></ref><ref id="CIT0071"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shane</surname><given-names>E</given-names></name><name><surname>Burr</surname><given-names>D</given-names></name><name><surname>Ebeling</surname><given-names>PR</given-names></name><etal>et al</etal></person-group><article-title>Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research</article-title><source>J Bone Miner Res</source><year>2010</year><volume>25</volume><fpage>2267</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">20842676</pub-id></element-citation></ref><ref id="CIT0072"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosla</surname><given-names>S</given-names></name><name><surname>Burr</surname><given-names>D</given-names></name><name><surname>Cauley</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research</article-title><source>J Bone Miner Res</source><year>2007</year><volume>22</volume><fpage>1479</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">17663640</pub-id></element-citation></ref><ref id="CIT0073"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>SL</given-names></name><name><surname>Landesberg</surname><given-names>R</given-names></name></person-group><article-title>Osteonecrosis of the jaw and the role of bisphosphonates: a critical review</article-title><source>Am J Med</source><year>2009</year><volume>122</volume><fpage>33</fpage><lpage>45</lpage></element-citation></ref><ref id="CIT0074"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strampel</surname><given-names>W</given-names></name><name><surname>Emkey</surname><given-names>R</given-names></name><name><surname>Civitelli</surname><given-names>R</given-names></name></person-group><article-title>Safety considerations with bisphosphonates for the treatment of osteoporosis</article-title><source>Drug Saf</source><year>2007</year><volume>30</volume><fpage>755</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17722968</pub-id></element-citation></ref><ref id="CIT0075"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migliaccio</surname><given-names>S</given-names></name><name><surname>Brama</surname><given-names>M</given-names></name><name><surname>Spera</surname><given-names>G</given-names></name></person-group><article-title>The differential effects of bisphosphonates, SERMs (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis</article-title><source>Clin Interv Aging</source><year>2007</year><volume>2</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">18044075</pub-id></element-citation></ref><ref id="CIT0076"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastell</surname><given-names>R</given-names></name><name><surname>Reid</surname><given-names>DM</given-names></name><name><surname>Vukicevic</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>The effects of lasofoxifene on bone turnover markers: the PEARL Trial</article-title><source>J Bone Miner Res</source><year>2008</year><volume>23</volume><issue>(Suppl 1)</issue><fpage>S81</fpage></element-citation></ref></ref-list></back></article>